Search

Background: The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease., Case Presentation: A 51-year-old healthy female developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bilateral pneumonia while vacationing in Colorado with her family. She was transferred to our facility for a higher level of care. Her respiratory status continued to deteriorate despite maximized critical care, including prone positioning ventilation and nitric oxide inhalation therapy. Veno-venous ECMO was initiated on hospital day 7 in conjunction with a 10-day course of compassionate use antiviral treatment with remdesivir. The patient's condition improved significantly and she was decannulated from ECMO on hospital day 17 (ECMO day 11). She was successfully extubated and eventually discharged to rehabilitation on hospital day 28., Conclusion: This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients., Competing Interests: Competing interestsMSF has served as scientific and educational consultant to Maquet Cardiovascular LLC, and as such has received funding for travel and financial support for educational activities related to ECMO technology. PFS is employed by HCA Healthcare in his role as the Chief Medical Officer at the Medical Center of Aurora. None of the other authors have relevant disclosures or conflicts of interest related to this manuscript. The CardioHelp™ extra-corporeal support system (Maquet Cardiovascular, Wayne, NJ) is not approved by the United States Food and Drug Administration for long-term use as described in this report., (© The Author(s) 2020.)